A Life Saving Hemostatic Agent and Risk of Thrombotic Complication
Keywords:
-Abstract
-
Downloads
References
Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus Proplex: A controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983;62:1135-8.
Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 1981,305:717-21.
Lusher JM. Thrombogenicity associated with factor X complex concentrates. Semin Hematol 1991;28:3-5.
Hedner U, Schulman S, Alberts KA, et al. Successful use of IFVIla in a patient with severe hemophilia A subjected to synovectomy. Lancet 1988;2:1193.
Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990;1:307-317.
Glazer S, Hedner U, Falch JF. Clinical update on the use of recombinant Factor VIIa. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC II, eds. Inhibitors to Coagulation Factors: Proceedings of the Second Intemational Symposium. New York: Plenum; 1995:163-74.
Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIla in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with hemophilia A and B, with and without inhibitors. Haemophilia 1998;4:790-8.
Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. The Journal of Trauma Injury, Infection and Critical Care 2001,51:431-9.
Blazek B, Hrdlicka R. Management of hemorrhage in trauma and surgery: our experience with recombinant activated factor VII. 7h Novo Nordisk Symposium on Haemostasis Management 2003:7.
Geeraedts LMG, Kamphuisen PW, Kaasjager HAH, Verwiel JMM, Frolke JPM. Is IFVIIa a panacea for persistent bleeding in trauma patients? A report of six cases. 7h Novo Nordisk Symposium on Haemostasis Management 2003:17.
Paluszkiewicz P, Misztal M, Paszczyk A. Administration of recombinant factor VIIa in severe polytrauma patients who underwent surgery due to massive bleeding. 7h Novo Nordisk Symposium on Haemostasis Management 2003:27.
Wahlgren C.-M., Swedenborg J. The use of recombinant activated factor VII to control bleeding during repair of a suprarenal abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2003;26:221-2.
Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, Gomez-Parra M, Arias FA, Guerrero-Aznar MD, Sendon-Perez A, Herrerias-Gutierrez JM. Recombinant activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clinical Gastroenterology and Hepatology 2004;2:78-84.
Douri MA, Shafi T, Khudairi DA, Bokhari EA, Black L, Akinwale N, Musa MO, Homaidhi AA, Fagih MA, Andreasen RB. Effect of the administration of recombinant activated factor VII (rFVIla; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagulation and Fibrinolysis 2000;11:S121-S127.
Berntorp E. Recombinant F'VIIa in the treatment of warfarin bleeding. Seminars in Thrombosis and Hemostasis 2000;26:433-6.
Monroe DM, Hoffman M, Allen GA, Robert HR. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Seminars in Thrombosis and Hemostasis 2000;26:373-7.
Bernstein D. Effectiveness of the recombinant factor VIla in patients with the coagulopathy of advanced child's B and C cirrhosis. Seminars in Thrombosis and Hemostasis 2000;26:437-40.
Chuansumrit A, Tangnararatchakit K, Lektakul Y, Pongthanapisith V, Nimjaroenniyom N, Thanarattanakorn P, Wongchanchailert M, Komwilaisak P. The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome. Blood Coagul Fibrinolysis 2004;15:335-42.
Veer CV, Mann KG. The regulation of the factor VII dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIla in refractory bleeding disorders. Seminars in Thrombosis and Hemostasis 2000;26:367-72.
Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagulation and Fibrinolysis 2000;11.S107-S111.
Giesen PLA, Nemerson Y. Tissue Factor on the Loose. Seminars in Thrombosis and Hemostasis 2000;26:379-84.
Hedner U. Recombinant factor VIA (NovoSeven as a hemostatic agent. Seminars in Hematology 2001;(suppl 12):S38-S43.
Erhardtsen E. Pharmacokinetics of Recombinant Activated Factor VII (rF'VIla). Seminars in Thrombosis and Hemostasis 2000;26:385-91.
Ng HJ, Loh YSM, HO LP, Tien SL. Two cases of thrombosis associated with use of recombinant factor VIla in Singapore. 7h Novo Nordisk Symposium on Haemostasis Management 2003:26.
Siegel LJ, Gerigk L, Tuettenberg J, Dempfle CE, Sharf J, Fiedler F. Cerebral sinus thrombosis in a trauma patient after recobinant activated factor VII infusion 7h Novo Nordisk Symposium on Haemostasis Management 2003:13.
Roberts HR. Recombinant Factor VIIa (NovoSeven and the Safety of Treatment. Seminars Hematol 2001;(suppl 12):S48-S50.
Abshire T, Keret G. Recombinant factor VIla: revien of efficacy, dosing regimens and safety in patient with congenital and acquired Factor II or IX inhibitors. J Thromb Haemost 2004:2:899-909.
Roberts HR, Monvoc DM, Hoffman M. Safety profile recombinant factor VIIa. Seminars Hematol. 2004;41 (suppl 1):S101-S108.
Abshire T. Dose optimization of recombinant factor VIla for control of mild to moderate bleeds in inhibitors patients: improved efficacy with higher dosing. Seminars Hematol 2004;41(suppl 1):S3-S7.
Hedner U. Doing with recombinant factor VIla based on current evidence. Seminars Haematol. 2004;41(suppl 1):S35-S39.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
